Novo Nordisk A/s

This study is testing whether a new once-weekly insulin injection works as well as the current standard daily insulin injection for controlling blood sugar in adults with type 1 diabetes. About 877 participants will use either the weekly insulin (icodec) or daily insulin (glargin…

This early-stage study is testing a new type of insulin (NNC0363-1063) to see how it interacts with a common non-glucose carbohydrate used in foods and drinks. It involves 36 adults with type 1 diabetes and will check if taking them together is safe and how the body processes the…

This early-stage study is testing whether a new drug called NNC0537-1482 is safe for people with heart failure. Researchers will give the drug or a placebo to 36 participants to see how their bodies handle it and check for side effects. The main goal is to understand the drug's s…

This early study is testing a new oral medicine called Inno8 in people with Hemophilia A to see if it's safe and how the body processes it. About 30 adult men with Hemophilia A will take different doses of the medicine over 11 weeks. Researchers will monitor for side effects and …

This study is testing whether a new drug called UBT251 is safe and helps people with overweight or obesity manage their weight. About 333 participants will be randomly assigned to receive either the actual drug or a placebo (inactive substance) for comparison. Researchers will me…

This study is testing a new, fast-acting insulin (called NNC0471-0119) for people with type 2 diabetes who use an insulin pump. Researchers want to see how quickly this new insulin gets into the blood, how long it works, and how well it lowers blood sugar compared to a commonly u…

This study is testing a new weekly injection called NNC0519-0130 to see if it can improve kidney function in people with chronic kidney disease who also have overweight or obesity. It will compare the new drug to an existing medication (semaglutide) and a placebo (a dummy injecti…

This large, late-stage study is testing whether a new medicine, NNC6019-0001, can help people with a serious heart condition called ATTR-CM. The condition is caused by a harmful protein building up in the heart. Researchers will see if the drug can lower the risk of heart-related…

This study follows 470 adults in Hungary with type 2 diabetes who are starting a pill called oral semaglutide as part of their regular doctor's care. Researchers will track changes in blood sugar control and body weight over about 6 months to see how well the treatment works in e…

This study is testing two new weekly injection drugs, CagriSema and cagrilintide, to see how well they help children and adolescents with overweight or obesity manage their weight. About 460 participants, aged 8 to 18, will receive either one of the new drugs, an existing drug (s…

This study is testing whether an experimental drug called ziltivekimab can reduce the fatty plaque buildup in heart arteries of people who recently had a heart attack. About 332 participants will be randomly assigned to receive either the drug or a placebo (dummy treatment) for 1…

This study aims to see if a new version of the diabetes pill oral semaglutide works as well and is as safe as the currently approved version. It involves about 264 Japanese adults with type 2 diabetes who will take one of the two pill versions for about 27 weeks. The main goal is…

This study is monitoring the safety and real-world performance of Awiqli, a once-weekly insulin, in people with diabetes in Japan. About 630 participants who are already prescribed this medication by their doctor will be observed for one year. Researchers will track side effects,…

This study is checking how safe the medicine eptacog alfa is for women in India who have severe bleeding after giving birth. The medicine helps stop heavy bleeding when standard treatments don't work. Researchers will follow 64 women for about a month to monitor for side effects …

This early-stage study is testing the safety and body's response to a new injectable medicine called NNC9733-0001 for type 2 diabetes. It involves 72 participants, including both healthy volunteers and people with type 2 diabetes, who receive either the medicine or a placebo inje…

This is the first time a new drug called NNC4004-0002 is being given to people. The study aims to see if it is safe and how well the body tolerates it in adults with high uric acid levels but no symptoms. Researchers will also check if a single injection can lower uric acid in th…

This program provides free, daily injections of the experimental drug concizumab to people with congenital haemophilia who cannot be adequately treated with currently approved medicines. It is designed for patients who have developed inhibitors to standard treatments or have poor…

This study is testing whether a monthly injection called ziltivekimab can help people with a common type of heart failure who also have body-wide inflammation. About 5,600 participants will receive either the real medicine or a placebo (dummy injection) for up to four years to se…

This study is testing different ways to increase the dose of an experimental weight management medication called NNC0519-0130. Researchers want to see if certain dosing methods can reduce side effects that might occur when people take the medication. The 24-week study involves 11…

This study is testing a new weekly injection called NNC0662-0419 to see if it is safe and helps people lose weight. It will involve about 220 adults living with overweight or obesity. Some participants will receive the new medicine, while others will get a placebo (an inactive sh…

This study is testing whether an investigational medicine called CDR132L can improve the structure and function of the heart in people with chronic heart failure. About 200 participants will be randomly assigned to receive either CDR132L or a placebo over a 60-week period. The ma…

This study is testing a new weekly injection called NNC0487-0111 to see if it helps people with obesity lose weight and is safe to use. About 1,150 participants will be randomly assigned to receive either the real injection or a placebo (a dummy injection with no medicine) once a…

This is an early-stage study to check the safety and basic effects of a new drug called NNC0363-1063 for type 1 diabetes. It will involve 154 healthy volunteers and people with type 1 diabetes to see how the body processes the drug and how it impacts blood sugar levels after meal…

This large, late-stage study is testing whether a new oral drug called etavopivat can reduce the number of painful blockages in blood vessels (called vaso-occlusive crises) in people aged 12 and older with sickle cell disease. Participants will be randomly assigned to receive eit…

This study compares a new once-weekly insulin injection (icodec) with standard daily basal insulin injections for people with type 2 diabetes. Researchers want to see if the weekly insulin works as well as daily insulin at controlling blood sugar levels in real-world medical prac…

This is the first study in humans to test the safety and side effects of a new drug called NNC4005-0001 for fatty liver disease. About 60 adults with increased body weight and liver fat will receive either the new drug or a placebo (a dummy pill with no medicine) in a single dose…

This study is testing how a new combination drug called CagriSema affects the body's energy use compared to a weight-loss diet. Eighty adults with obesity will be randomly assigned to receive either the drug or follow a reduced-calorie diet for part of the study, then all will re…

This study is testing whether an experimental medicine called CDR132L can improve the structure and function of the heart in people with a specific type of heart failure. About 200 participants will be randomly assigned to receive either CDR132L or a placebo over a 60-week period…

This early-stage study is testing whether a new experimental drug called NNC6989-0001 is safe for people with overweight or obesity. The trial will enroll 96 healthy adults to receive either the drug or a placebo, with researchers carefully monitoring for side effects. This is th…

This study is observing how well a new weekly insulin injection, called insulin icodec, controls blood sugar in real-world settings for adults with type 1 diabetes. It will follow 245 participants for about 6-7 months to see if the weekly shot improves blood sugar levels, makes t…

This study is testing whether a new, unapproved drug called ziltivekimab can help prevent future heart attacks, strokes, or death in people who have just had a heart attack. About 10,000 participants will give themselves a monthly injection of either the real drug or a placebo (d…

This study aims to understand the long-term safety and effectiveness of etavopivat, an investigational drug for sickle cell disease and thalassemia. It will follow about 480 adults, adolescents, and children who have already taken etavopivat in a previous study and benefited from…

This study is testing whether an investigational drug called ziltivekimab can improve daily symptoms and physical abilities in people with a common type of heart failure who also have body-wide inflammation. About 680 participants will be randomly assigned to receive either the d…

This study is a long-term safety check for people who previously received an experimental obesity drug called INV-347 in an earlier trial. Participants will not receive any new treatment; researchers will monitor their health and measure how long the drug stays in their system. T…

This is a first-in-human study to check if a new medicine called Inno8 is safe and how it behaves in the body. It will involve 108 healthy male volunteers who will receive the drug or a placebo via injection or pill. The main goal is to gather safety information to support future…

This study aims to understand how a specific medicine for Hemophilia A is used in everyday practice in Iraq. Researchers will look back at the medical records of about 900 male patients, both children and adults, who have switched to this treatment. The goal is to collect informa…

This study aims to understand how eating before and after taking a new oral medicine called Inno8 affects how the body absorbs it. It will involve 80 healthy male volunteers who will take a single dose under different fasting conditions. The main goal is to gather data to help de…

This study aims to understand how fasting and temporarily stopping popular GLP-1 weight-loss medications affect how quickly food leaves the stomach. It will involve 75 people with obesity who are already taking specific doses of liraglutide or semaglutide. Researchers will use ul…